CN Patent

CN114173816A — 通过施用il-4r拮抗剂治疗特应性皮炎的方法

Assigned to Regeneron Pharmaceuticals Inc · Expires 2022-03-11 · 4y expired

What this patent protects

提供了治疗儿科个体的中度至重度或重度特应性皮炎的方法。在一个方面中，该方法包括给个体施用一个或多个剂量的白介素‑4受体(IL‑4R)拮抗剂，如抗IL‑4R抗体或其抗原结合片段。

USPTO Abstract

提供了治疗儿科个体的中度至重度或重度特应性皮炎的方法。在一个方面中，该方法包括给个体施用一个或多个剂量的白介素‑4受体(IL‑4R)拮抗剂，如抗IL‑4R抗体或其抗原结合片段。

Drugs covered by this patent

Patent Metadata

Patent number
CN114173816A
Jurisdiction
CN
Classification
—
Expires
2022-03-11
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.